
Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Fund Concussion Trials and R&D
Oragenics Inc. secures up to $20 million through a preferred stock and warrant offering to advance its ONP-2 concussion trials and support research and development efforts.
Read full story

























